NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyDisease-modifying effects of NRF2 activators in a nerve agent exposure model
About This Grant
ABSTRACT Organophosphate (OP) nerve agents (OPNA) are increasingly used to target civilians and often as chemical warfare agents. There is no treatment for OPNA survivors. Limiting the life-long health consequences of OPNA exposure is as important as preventing deaths due to acute exposure to OPNAs, which are cholinesterase inhibitors and potent seizurogenic agents. In animal models, acute OPNA exposure induces status epilepticus (SE) and other cholinergic symptoms. The current medical countermeasures (MCM), such as atropine, oxime, and diazepam/midazolam, control symptoms but do not prevent long-term neurotoxicity and the development of epilepsy that are primarily due to persistent brain injury. We predict that combining neuroprotectants and MCMs will prevent OPNA-induced long-term neurotoxicity. We will investigate the long-term neuroprotective effect of novel activators of the Nuclear factor erythroid-2–Related Factor 2 (NRF2), a potential regulator of endogenous antioxidants. We will test the non-electrophilic small molecules of NRF2 activators as novel disease-modifying drugs in a rat diisopropylfluorophosphate (DFP) model. DFP is a surrogate for OPNAs. We and others have demonstrated nitrooxidative stress, neuroinflammation, and neurodegeneration in OPNA models. Treating with either an inducible nitric oxide synthase (iNOS) inhibitor, 1400W, or an NADPH oxidase 2 (NOX2) inhibitor, diapocynin, mitigated the DFP-induced nitrooxidative stress and brain pathology, suggesting the antioxidant mechanism as a potential therapeutic target for disease- modification. Our studies also indicated that 1400W and diapocynin/mitoapocynin increased the total glutathione in the serum. Therefore, the drugs that directly promote endogenous glutathione synthesis could be useful as a therapeutic agent to mitigate OPNA-induced long-term neurotoxicity. We will test two NRF2 activators, RTA408 and IND22. RTA408 is in clinical trials for other diseases and demonstrated its’ disease- modifying potential in a rat kainate model of chronic epilepsy. Therefore, RTA408 will be a positive control for testing the efficacy of a novel NRF2 activator, IND22, which is also a non-electrophilic small molecule, blood- brain-barrier permeable, and its pharmacokinetics are promising. Our overarching hypothesis is that NRF2 activators will counteract OPNA-induced oxidative stress, neurodegeneration, and epileptogenesis and restore brain function. We will investigate the short-term effects of the test drugs in a mixed-sex cohort of a rat DFP model (Specific Aim 1) and validate the lead compound for behavioral, structural, and functional MRI, video- EEG, and histological outcomes in the long-term study (Specific Aim 2). To determine the protective effect of NRF2 activators, we will quantify nitrooxidative stressors, cytokines, and brain immunohistochemistry for neurodegeneration and neuroinflammation markers. Our research proposal, per (PAR-25-114), “directly advances the discovery of novel treatment strategies that address serious morbidity (due to long-term neurotoxicity and seizures) and mortality after acute exposure to highly toxic chemical threats.”
Grant Summary
Disease-modifying effects of NRF2 activators in a nerve agent exposure model is a OD - NIH Office of the Director grant providing up to $393K for university, nonprofit, healthcare org. Applications are due 2028-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $393K
2028-06-30
- 1Confirm your organization is eligible for Disease-modifying effects of NRF2 activators in a nerve agent exposure model from OD - NIH Office of the Director, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to OD - NIH Office of the Director before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against OD - NIH Office of the Director's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Disease-modifying effects of NRF2 activators in a nerve agent exposure model: Frequently Asked Questions
Who is eligible for the Disease-modifying effects of NRF2 activators in a nerve agent exposure model?
Disease-modifying effects of NRF2 activators in a nerve agent exposure model is offered by OD - NIH Office of the Director and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Disease-modifying effects of NRF2 activators in a nerve agent exposure model provide?
Disease-modifying effects of NRF2 activators in a nerve agent exposure model provides up to $393K per award from OD - NIH Office of the Director. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Disease-modifying effects of NRF2 activators in a nerve agent exposure model deadline?
Applications for Disease-modifying effects of NRF2 activators in a nerve agent exposure model are due 2028-06-30 (open). Because deadlines can change, verify the date with the funder, OD - NIH Office of the Director, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Disease-modifying effects of NRF2 activators in a nerve agent exposure model?
To apply for Disease-modifying effects of NRF2 activators in a nerve agent exposure model, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from OD - NIH Office of the Director.